Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2013 | -941.52 Thousand USD | 42.78% |
| 2012 | -1.64 Million USD | 42.91% |
| 2011 | -2.88 Million USD | -662.47% |
| 2010 | 512.41 Thousand USD | 104.75% |
| 2009 | -10.77 Million USD | 48.31% |
| 2008 | -20.84 Million USD | -6.65% |
| 2007 | -19.54 Million USD | 25.83% |
| 2006 | -26.35 Million USD | -129.15% |
| 2005 | -11.5 Million USD | -2.23% |
| 2004 | -11.25 Million USD | -34.45% |
| 2003 | -8.36 Million USD | 23.88% |
| 2002 | -10.99 Million USD | -7.22% |
| 2001 | -10.25 Million USD | 3.77% |
| 2000 | -10.65 Million USD | 23.9% |
| 1999 | -14 Million USD | -102.9% |
| 1998 | -6.9 Million USD | 13.75% |
| 1997 | -8 Million USD | -33.33% |
| 1996 | -6 Million USD | 57.45% |
| 1995 | -14.1 Million USD | -69.88% |
| 1994 | -8.3 Million USD | 66.93% |
| 1993 | -25.1 Million USD | -56.88% |
| 1992 | -16 Million USD | -15.94% |
| 1991 | -13.8 Million USD | -58.62% |
| 1990 | -8.7 Million USD | 0.0% |
| 1989 | -8.7 Million USD | 33.08% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2014 Q1 | -332.01 Thousand USD | -238.89% |
| 2014 Q2 | -321 Thousand USD | 3.32% |
| 2013 Q2 | -520.05 Thousand USD | -74.6% |
| 2013 Q4 | 239.04 Thousand USD | 165.91% |
| 2013 FY | -941.52 Thousand USD | 42.78% |
| 2013 Q3 | -362.66 Thousand USD | 30.26% |
| 2013 Q1 | -297.85 Thousand USD | 35.12% |
| 2012 Q2 | -294.9 Thousand USD | 7.64% |
| 2012 Q4 | -459.1 Thousand USD | 19.76% |
| 2012 FY | -1.64 Million USD | 42.91% |
| 2012 Q1 | -319.3 Thousand USD | 59.85% |
| 2012 Q3 | -572.16 Thousand USD | -94.01% |
| 2011 FY | -2.88 Million USD | -662.47% |
| 2011 Q2 | -533.53 Thousand USD | 50.44% |
| 2011 Q4 | -795.36 Thousand USD | -66.85% |
| 2011 Q3 | -476.7 Thousand USD | 10.65% |
| 2011 Q1 | -1.07 Million USD | -31.62% |
| 2010 Q3 | 4.83 Million USD | 394.02% |
| 2010 Q4 | -817.97 Thousand USD | -116.92% |
| 2010 Q1 | -1.85 Million USD | -5.97% |
| 2010 Q2 | -1.64 Million USD | 11.57% |
| 2010 FY | 512.41 Thousand USD | 104.75% |
| 2009 Q2 | -2.61 Million USD | 39.88% |
| 2009 FY | -10.77 Million USD | 48.31% |
| 2009 Q4 | -1.75 Million USD | 14.86% |
| 2009 Q1 | -4.34 Million USD | -1.23% |
| 2009 Q3 | -2.06 Million USD | 21.18% |
| 2008 Q2 | -6.11 Million USD | -14.81% |
| 2008 Q1 | -5.32 Million USD | 2.08% |
| 2008 FY | -20.84 Million USD | -6.65% |
| 2008 Q4 | -4.29 Million USD | 15.96% |
| 2008 Q3 | -5.11 Million USD | 16.41% |
| 2007 FY | -19.54 Million USD | 25.83% |
| 2007 Q4 | -5.43 Million USD | -14.86% |
| 2007 Q1 | -4.08 Million USD | 71.76% |
| 2007 Q2 | -5.29 Million USD | -29.69% |
| 2007 Q3 | -4.73 Million USD | 10.53% |
| 2006 Q1 | -3.96 Million USD | -23.52% |
| 2006 FY | -26.35 Million USD | -129.15% |
| 2006 Q3 | -4.01 Million USD | -2.24% |
| 2006 Q2 | -3.92 Million USD | 1.0% |
| 2006 Q4 | -14.45 Million USD | -260.22% |
| 2005 Q2 | -2.39 Million USD | -2.29% |
| 2005 Q1 | -2.34 Million USD | -20.2% |
| 2005 FY | -11.5 Million USD | -2.23% |
| 2005 Q3 | -3.54 Million USD | -48.05% |
| 2005 Q4 | -3.2 Million USD | 9.59% |
| 2004 Q2 | -4.02 Million USD | -47.95% |
| 2004 Q4 | -1.95 Million USD | 23.53% |
| 2004 Q3 | -2.55 Million USD | 36.69% |
| 2004 Q1 | -2.72 Million USD | -29.93% |
| 2004 FY | -11.25 Million USD | -34.45% |
| 2003 Q2 | -1.9 Million USD | 19.21% |
| 2003 Q4 | -2.09 Million USD | -3.85% |
| 2003 Q3 | -2.01 Million USD | -6.12% |
| 2003 FY | -8.36 Million USD | 23.88% |
| 2003 Q1 | -2.35 Million USD | 18.87% |
| 2002 FY | -10.99 Million USD | -7.22% |
| 2002 Q4 | -2.9 Million USD | -17.15% |
| 2002 Q1 | -3.01 Million USD | -25.49% |
| 2002 Q2 | -2.59 Million USD | 14.03% |
| 2002 Q3 | -2.47 Million USD | 4.62% |
| 2001 Q3 | -2.49 Million USD | 23.01% |
| 2001 Q4 | -2.4 Million USD | 3.36% |
| 2001 FY | -10.25 Million USD | 3.77% |
| 2001 Q1 | -2.12 Million USD | -45.86% |
| 2001 Q2 | -3.23 Million USD | -52.44% |
| 2000 Q4 | -1.45 Million USD | 50.19% |
| 2000 Q2 | -3.32 Million USD | -12.78% |
| 2000 Q1 | -2.95 Million USD | 52.4% |
| 2000 FY | -10.65 Million USD | 23.9% |
| 2000 Q3 | -2.92 Million USD | 12.26% |
| 1999 Q3 | -4.1 Million USD | -156.25% |
| 1999 FY | -14 Million USD | -102.9% |
| 1999 Q4 | -6.2 Million USD | -51.22% |
| 1999 Q2 | -1.6 Million USD | 23.81% |
| 1999 Q1 | -2.1 Million USD | -10.53% |
| 1998 FY | -6.9 Million USD | 13.75% |
| 1998 Q3 | -1.6 Million USD | 5.88% |
| 1998 Q1 | -1.6 Million USD | 23.81% |
| 1998 Q4 | -1.9 Million USD | -18.75% |
| 1998 Q2 | -1.7 Million USD | -6.25% |
| 1997 Q1 | -1.7 Million USD | 22.73% |
| 1997 FY | -8 Million USD | -33.33% |
| 1997 Q4 | -2.1 Million USD | 0.0% |
| 1997 Q3 | -2.1 Million USD | 0.0% |
| 1997 Q2 | -2.1 Million USD | -23.53% |
| 1996 Q2 | -1.1 Million USD | 26.67% |
| 1996 FY | -6 Million USD | 57.45% |
| 1996 Q4 | -2.2 Million USD | -100.0% |
| 1996 Q3 | -1.1 Million USD | 0.0% |
| 1996 Q1 | -1.5 Million USD | -36.36% |
| 1995 Q3 | -1.1 Million USD | 90.35% |
| 1995 Q1 | -600 Thousand USD | -50.0% |
| 1995 FY | -14.1 Million USD | -69.88% |
| 1995 Q4 | -1.1 Million USD | 0.0% |
| 1995 Q2 | -11.4 Million USD | -1800.0% |
| 1994 Q2 | -3.3 Million USD | 13.16% |
| 1994 Q1 | -3.8 Million USD | 61.62% |
| 1994 Q4 | -400 Thousand USD | 42.86% |
| 1994 Q3 | -700 Thousand USD | 78.79% |
| 1994 FY | -8.3 Million USD | 66.93% |
| 1993 Q3 | -5 Million USD | -13.64% |
| 1993 Q1 | -5.8 Million USD | -23.4% |
| 1993 FY | -25.1 Million USD | -56.88% |
| 1993 Q4 | -9.9 Million USD | -98.0% |
| 1993 Q2 | -4.4 Million USD | 24.14% |
| 1992 Q2 | -2.9 Million USD | 12.12% |
| 1992 Q4 | -4.7 Million USD | 6.0% |
| 1992 Q3 | -5 Million USD | -72.41% |
| 1992 Q1 | -3.3 Million USD | 17.5% |
| 1992 FY | -16 Million USD | -15.94% |
| 1991 Q1 | -3.3 Million USD | 0.0% |
| 1991 Q3 | -2.9 Million USD | 0.0% |
| 1991 Q2 | - USD | 100.0% |
| 1991 FY | -13.8 Million USD | -58.62% |
| 1991 Q4 | -4 Million USD | -37.93% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 FY | -8.7 Million USD | 0.0% |
| 1989 FY | -8.7 Million USD | 33.08% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 29.496% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 86.517% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 101.777% |
| Nascent Biotech, Inc. | -2.08 Million USD | 54.901% |
| Rebus Holdings, Inc. | -1.02 Million USD | 7.693% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.446% |
| Qrons Inc. | -789.34 Thousand USD | -19.279% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -48.88% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.496% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -126.613% |
| Skye Bioscience, Inc. | -37.64 Million USD | 97.499% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.744% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 85.683% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -244.375% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.815% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 67.448% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 48.283% |
| Mesoblast Limited | -87.95 Million USD | 98.93% |
| Marizyme, Inc. | -65.34 Million USD | 98.559% |
| Genus plc | 7.9 Million USD | 111.918% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 91.356% |
| Pharming Group N.V. | -10.54 Million USD | 91.074% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 56.608% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 74.623% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 89.354% |
| ContraFect Corporation | -65.15 Million USD | 98.555% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 80.73% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 45.496% |
| IMV Inc. | -36.48 Million USD | 97.419% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 88.318% |
| MultiCell Technologies, Inc. | -380.07 USD | -247625.156% |
| ONE Bio Corp. | 8.67 Million USD | 110.851% |
| Accustem Sciences Inc. | -3.74 Million USD | 74.869% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 98.179% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 25.696% |
| Q BioMed Inc. | -2.05 Million USD | 54.119% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 74.778% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 60.454% |
| Biomind Labs Inc. | -1.21 Million USD | 22.464% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.424% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 69.645% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 88.087% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 51.698% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -6186.919% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 94.068% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 83.815% |
| GB Sciences, Inc. | -1.36 Million USD | 30.855% |
| Alpha Cognition Inc. | -13.77 Million USD | 93.164% |
| HST Global, Inc. | -146.21 Thousand USD | -543.957% |
| CSL Limited | 2.64 Billion USD | 100.036% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 46.345% |
| Halberd Corporation | -79.67 Thousand USD | -1081.697% |
| Enzolytics Inc. | -2.17 Million USD | 56.748% |
| Agentix Corp. | -1.37 Million USD | 31.486% |
| Resverlogix Corp. | -3.61 Million USD | 73.919% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 70.312% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.681% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1060.744% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 113.597% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 76.302% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 68.887% |
| AVAX Technologies, Inc. | -6.41 Million USD | 85.32% |
| Zenith Capital Corp. | -10.59 Million USD | 91.114% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.014% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -3950.981% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 77.29% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1457.775% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 53.044% |
| Kadimastem Ltd | -3.3 Million USD | 71.533% |
| Helix BioMedix, Inc. | -1.05 Million USD | 10.845% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 75.346% |
| BioStem Technologies, Inc. | -8.48 Million USD | 88.901% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -113.32% |
| LadRx Corporation | 400.44 Thousand USD | 335.122% |
| Cell Source, Inc. | -5.32 Million USD | 82.306% |
| Regen BioPharma, Inc. | 1.02 Million USD | 191.99% |
| Regen BioPharma, Inc. | 1.02 Million USD | 191.99% |
| NovAccess Global Inc. | -4.76 Million USD | 80.258% |
| Affymax, Inc. | -14.42 Million USD | 93.472% |
| Itoco Inc. | -1.86 Million USD | 49.624% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 78.806% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 43.587% |
| Mobile Lads Corp. | -2.26 Million USD | 58.4% |
| CytoDyn Inc. | -49.84 Million USD | 98.111% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1091.311% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -312.721% |
| SYBLEU INC | -180.3 Thousand USD | -422.19% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 41.619% |
| International Stem Cell Corporation | -131 Thousand USD | -618.724% |
| Bioxytran, Inc. | -4.28 Million USD | 78.002% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1634.834% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 62.789% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 98.041% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 55.462% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -20.572% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 70.28% |
| Neutra Corp. | -233.46 Thousand USD | -303.285% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 95.36% |
| PureTech Health plc | -65.69 Million USD | 98.567% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 95.573% |
| IXICO plc | -1.17 Million USD | 20.074% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 90.515% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 98.352% |
| CSL Limited | 2.64 Billion USD | 100.036% |
| Cellectis S.A. | -103.17 Million USD | 99.087% |